公开(公告)号：US20180319778A1

公开(公告)日：2018-11-08

申请号：US15769987

申请日：2016-10-20

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education ,  National Institute of Health, A Component of the U.S Department of Health and Human Services ,  The Regents of the University of California

发明人： Donna M. HURYN ,  Peter Wipf ,  Matthew G. LaPorte ,  Raffaele Colombo ,  Marina Kovaliov ,  Chaemin Lim ,  Celeste Natalie Alverez ,  Zhizhou Yue ,  Lalith Palitha Samankumara ,  Alexander Julian Chatterley ,  Yongzhao Yan ,  Mary Liang ,  Neal J. Green ,  Eric T. Baldwin ,  William J. Moore ,  Michelle Arkin ,  R. Jeffrey Neilz ,  Kean-Hooi Ang ,  Cliffford Bryant ,  Stacie Bulfer

IPC分类号： C07D405/14 ,  C07D401/14 ,  C07D401/10 ,  C07D413/14 ,  C07D417/14 ,  A61P25/28 ,  A61P35/00

CPC分类号： C07D405/14 ,  A61K31/404 ,  A61K31/454 ,  A61K31/496 ,  A61P25/28 ,  A61P35/00 ,  C07D401/10 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14

摘要： The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.

公开(公告)号：US20200157082A1

公开(公告)日：2020-05-21

申请号：US16748654

申请日：2020-01-21

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education ,  National Institutes of Health, A Component of the U.S. Department of Health and Human Services ,  The Regents of the University of California

发明人： Donna M. Huryn ,  Peter Wipf ,  Matthew G. LaPorte ,  Raffaele Colombo ,  Marina Kovaliov ,  Chaemin Lim ,  Celeste Natalie Alverez ,  Zhizhou Yue ,  Lalith Palitha Samankumara ,  Alexander Julian Chatterley ,  Yongzhao Yan ,  Mary Liang ,  Neal J. Green ,  Eric T. Baldwin ,  William J. Moore ,  Michelle Arkin ,  R. Jeffrey Neitz ,  Kean-Hooi Ang ,  Clifford Bryant ,  Stacie Bulfer

IPC分类号： C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  A61P35/00 ,  A61P25/28 ,  C07D401/10 ,  C07D401/14

摘要： The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.

公开(公告)号：US20220112179A1

公开(公告)日：2022-04-14

申请号：US17556147

申请日：2021-12-20

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education ,  National Institutes of Health, A component of the United States Department of Health and Human Servi ,  The Regents of the University of California

发明人： Donna M. Huryn ,  Peter Wipf ,  Matthew G. LaPorte ,  Raffaele Colombo ,  Marina Kovaliov ,  Chaemin Lim ,  Celeste Natalie Alverez ,  Zhizhou Yue ,  Lalith Palitha Samankumara ,  Alexander Julian Chatterley ,  Yongzhao Yan ,  Mary Liang ,  Neal J. Green ,  Eric T. Baldwin ,  William J. Moore ,  Michelle Arkin ,  R. Jeffrey Neitz ,  Kean-Hooi Ang ,  Clifford Bryant ,  Stacie Bulfer

IPC分类号： C07D405/14 ,  A61P35/00 ,  C07D401/10 ,  C07D413/14 ,  C07D401/14 ,  C07D417/14 ,  A61P25/28

摘要： The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.

公开(公告)号：US11247985B2

公开(公告)日：2022-02-15

申请号：US16748654

申请日：2020-01-21

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education ,  National Institutes of Health, A Component of the United States Department of Health and Human Services ,  The Regents of the University of California

发明人： Donna M. Huryn ,  Peter Wipf ,  Matthew G. LaPorte ,  Raffaele Colombo ,  Marina Kovaliov ,  Chaemin Lim ,  Celeste Natalie Alverez ,  Zhizhou Yue ,  Lalith Palitha Samankumara ,  Alexander Julian Chatterley ,  Yongzhao Yan ,  Mary Liang ,  Neal J. Green ,  Eric T. Baldwin ,  William J. Moore ,  Michelle Arkin ,  R. Jeffrey Neitz ,  Kean-Hooi Ang ,  Clifford Bryant ,  Stacie Bulfer

IPC分类号： C07D401/10 ,  A61P35/00 ,  C07D405/14 ,  C07D401/14 ,  A61P25/28 ,  C07D413/14 ,  C07D417/14

摘要： The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.

公开(公告)号：US10752629B2

公开(公告)日：2020-08-25

申请号：US16193269

申请日：2018-11-16

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Peter Wipf ,  Stephen D. Meriney ,  Mary Liang

IPC分类号： C07D473/16 ,  A61K31/52 ,  A61K31/495 ,  A61P21/00 ,  A61K45/06 ,  A61K31/375 ,  A61K31/53 ,  C07D487/04

摘要： Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.

公开(公告)号：US20180009810A1

公开(公告)日：2018-01-11

申请号：US15711715

申请日：2017-09-21

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Peter Wipf ,  Stephen D. Meriney ,  Mary Liang

IPC分类号： C07D473/16 ,  A61K31/53 ,  A61K31/375 ,  A61K31/52 ,  C07D487/04 ,  A61K45/06

CPC分类号： C07D473/16 ,  A61K31/375 ,  A61K31/52 ,  A61K31/53 ,  A61K45/06 ,  C07D487/04 ,  Y02A50/469 ,  A61K2300/00

摘要： Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.

公开(公告)号：US20240051931A1

公开(公告)日：2024-02-15

申请号：US18039941

申请日：2021-12-02

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Peter Wipf ,  Donna M. Huryn ,  Matthew G. LaPorte ,  Leila Terrab ,  Michael James Houghton ,  Andrea Topacio ,  Taber Sarah Maskrey ,  Tyler Kristufek ,  Uygar Sozer ,  Desirae Lynn Crocker ,  Sipak Joyasawal ,  Alyssa Thornton ,  Shikha Singh Chauhan ,  Mary Liang ,  Prema Iyer ,  Jagannath Panda

IPC分类号： C07D311/66 ,  C07D405/12 ,  C07D265/36 ,  C07D405/04

CPC分类号： C07D311/66 ,  C07D405/12 ,  C07D265/36 ,  C07D405/04

摘要： The present disclosure is directed to chromane compounds, chromane compounds demonstrating HDAC inhibition, and pharmaceutical compositions thereof. Additional embodiments include methods of using the chromane compounds. For example, the disclosure includes methods of inhibiting histone acetylation in a cell, comprising contacting the cell with a chromane compound of the disclosure. Additional embodiments include methods of treating a disease capable of treatment by inhibition of histone acetylation in a patient in need thereof, comprising administering a chromane compound of the disclosure.

公开(公告)号：US10174031B2

公开(公告)日：2019-01-08

申请号：US15711715

申请日：2017-09-21

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Peter Wipf ,  Stephen D. Meriney ,  Mary Liang

IPC分类号： A61K31/495 ,  A61K31/52 ,  C07D473/16 ,  C07D487/04 ,  A61K31/53 ,  A61K45/06 ,  A61K31/375

摘要： Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.

公开(公告)号：US20190084984A1

公开(公告)日：2019-03-21

申请号：US16193269

申请日：2018-11-16

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Peter Wipf ,  Stephen D. Meriney ,  Mary Liang

IPC分类号： C07D473/16 ,  C07D487/04 ,  A61K31/53 ,  A61K31/52 ,  A61K45/06 ,  A61K31/375

摘要： Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.